Skip NavigationSkip to Content
Return Return to Search Results

Utilization of a nitrobenzoxadiazole (NBD) fluorophore in the design of a Grb2 SH2 domain-binding peptide mimetic

  1. Author:
    Shi, Z. D.
    Karki, R. G.
    Oishi, S.
    Worthy, K. M.
    Bindu, L. K.
    Dharmawardana, P. G.
    Nicklaus, M. C.
    Bottaro, D. P.
    Fisher, R. J.
    Burke, T. R.

  2. Author Address

    NCI, CCR, Med Chem Lab, NIH, Frederick, MD 21702 USA. SAIC Frederick, Prot Chem Lab, Frederick, MD 21702 USA. NCI, CCR, Urol Oncol Branch, NIH, Bethesda, MD 21702 USA Burke, TR, NCI, CCR, Med Chem Lab, NIH, Frederick, MD 21702 USA
    1. Year: 2005
    2. Date: MAR 1
  2. Journal: Bioorganic & Medicinal Chemistry Letters
    1. 15
    2. 5
    3. Pages: 1385-1388
  4. Type of Article: Article
  1. Abstract:

    Fluorescence labeling has become a general technique for studying the intracellular accumulation and localization of exogenously administered materials. Reported herein is a low nanomolar affinity Grb2 SH2 domain-binding antagonist that utilizes the environmentally-sensitive nitrobenzoxadiazole (NBD) fluorophore as a naphthyl replacement. This novel agent should serve as a useful tool to visualize the actions of this class of Grb2 SH2 domain-binding antagonists in whole cell systems. (c) 2005 Elsevier Ltd. All rights reserved

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.bmcl.2005.01.017
  3. View record in Web of Science®
  4. WOS: 000227371000023

Library Notes

  1. No notes added.
NCI at FrederickClose Button

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel